Panelists discuss how spinal muscular atrophy is an autosomal recessive genetic disease affecting motor neurons with 3 currently approved disease-modifying therapies that restore SMN protein ...

More than two years after the Government committed to adding SMA to newborn testing, families are still waiting ...

The tiny zebrafish is helping researchers rapidly determine whether a newborn’s genetic mutation is likely to cause spinal ...

Credit: Novartis. The approval was supported by data from phase 3 STEER study, which enrolled patients with SMA who were treatment-naive and able to sit but never able to walk independently. Itvisma ...

With a tank of zebrafish, Queensland researcher Jean Giacomotto was able to test a never-before seen genetic variant ...

The tiny zebrafish is helping researchers rapidly determine whether a newborn's genetic mutation is likely to cause spinal ...

CHESTERFIELD COUNTY, Va. (WRIC) — Spinal Muscular Atrophy (SMA) is a genetic disease that severely weakens muscles and causes developmental delays. It affects one in 10,000 American babies in the U.S.

SMA is a neurodegenerative genetic disorder that affects the muscle strength and movement of a baby before birth. The study found that the child did not show any identifiable features of SMA even ...

A couple whose son died from a rare genetic condition are encouraging others to take part in screening which they say could ...

Spinal Muscular Atrophy companies are Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst ...